In this week’s faculty highlight, we present Dr. Joseph Rosales.
Dr. Rosales joined us as faculty at the Multidisciplinary Thoracic Oncology Conference in Seattle, WA on October 22, 2022.
Our staff, Tiani, talked with Dr. Rosales to discuss his roles in the conference and his involvement with the Binaytara Foundation.
Dr. Rosales, an oncologist at Virginia Mason, was a moderator at the recent Thoracic Oncology Conference. He has been involved in the weekly tumor board that the Foundation hosts for doctors in Nepal and in various other roles. We are blessed by his support and dedication to our mission and goals.
Watch the video to hear more!
The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal. Donate here to change lives!
2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty faculty highlight FDA approved Featured head & neck cancer surgery in Nepal healthcare equity hematological malignancies Journal leukemia Lung cancer lymphoma multiple myeloma Nepal Nepal cancer care oncology oncology CME Opinion peer-reviewed journal SCHD upcoming conferences video news Volunteer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal
MoreOn March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients
MoreBy Dr. Chepsy Philip Believers Church Medical College Hospital Care of hematological cancers in India and other low- and middle-income countries
MoreOn February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC)
MoreDr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase
More